GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Pretax Margin %

Thiogenesis Therapeutics (TSXV:TTI) Pretax Margin % : % (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Thiogenesis Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was C$-0.66 Mil. Thiogenesis Therapeutics's Revenue for the three months ended in Sep. 2024 was C$0.00 Mil. Therefore, Thiogenesis Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was %.

The historical rank and industry rank for Thiogenesis Therapeutics's Pretax Margin % or its related term are showing as below:


TSXV:TTI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -148.6
* Ranked among companies with meaningful Pretax Margin % only.

Thiogenesis Therapeutics Pretax Margin % Historical Data

The historical data trend for Thiogenesis Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Pretax Margin % Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23
Pretax Margin %
- - - - -

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Thiogenesis Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Thiogenesis Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thiogenesis Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Pretax Margin % falls into.



Thiogenesis Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Thiogenesis Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-5.063/0
= %

Thiogenesis Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-0.657/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Thiogenesis Therapeutics  (TSXV:TTI) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Thiogenesis Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Thiogenesis Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder